The skeleton is a complex tissue, and hormonal control of bone remodelling is elaborate. The important role that steroid hormones play in bone cell development and in the maintenance of normal bone architecture is well established, but it is only relatively recently that it has become possible to describe their precise mechanism of action. This review focuses not only on the steroid hormones (oestrogens, corticosteroids, androgens and progesterone), but also on related hormones (vitamin D, thyroid hormone and the retinoids), all of which act via structurally homologous nuclear receptors that form part of the steroid/thyroid receptor superfamily. By examining the actions of all of these hormones in vivo and in vitro, this review gives a general overview of the current understanding of steroid hormone action in bone. In addition, a comprehensive review of steroid hormone receptor expression in bone cells is included. Finally, the role that future developments, such as steroid hormone receptor knockout mice, will play in our understanding of steroid hormone action in bone is considered.
INTRODUCTION
Bone is a highly metabolically active tissue in which the processes of osteoblastic bone formation and osteoclastic resorption are continuous throughout life. Coupling of osteoblast and osteoclast action ensures that normal bone structure is maintained. A loss of bone homoeostasis may result in a decrease in bone mass and deterioration of the microarchitecture of the skeleton (osteoporosis), or a defect in the mineralization of bone, such as that seen in osteomalacia. Osteoporosis has huge health implications affecting both men and women. It has been estimated that, in the U.S.A., at least 90 % of all hip and spine fractures among elderly white women and more than 70 % of those among elderly white men may be attributed to osteoporosis [1] . Although there is a gradual loss of bone during life, which is accelerated in postmenopausal women, two factors that affect the degree of osteoporosis are the peak bone mass achieved and the rate of bone loss. Many factors influence the peak bone mass and the rate of bone loss, including gender, environmental factors such as diet, calcium intake and the level of exercise, and genetic factors ; these have been reviewed in detail elsewhere [2, 3] .
The control of bone formation and resorption is influenced locally by factors such as cytokines (both paracrine and autocrine), growth factors, mechanical loading, nitric oxide, and cell-cell communications [4] [5] [6] [7] [8] . Systemic control is exerted through the action of cytokines, growth factors and hormones [9, 10] . Endocrine regulation occurs either by hormones acting at the cell membrane, for example the classical bone hormones parathyroid hormone and calcitonin [11, 12] , or by other hormones, such as growth hormone and insulin [9] .
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Additionally, evidence from a number of in vitro, in vivo and clinical studies clearly indicates a role for steroid hormones in the regulation of normal bone development and the maintenance of intact bone.
SKELETAL ACTIONS OF STEROID HORMONES
Bone remodelling is a complex process involving a number of stages. Quiescent bone is covered by flat bone-lining cells. In response to a bone-resorbing stimulus, osteoclastic migration and bone resorption are activated. Osteoclasts then begin to remove both organic matrix and mineral content of bone to produce a pit (Howslip's lacuna). During the reversal phase, macrophage-like mononuclear cells smooth the surface and begin to deposit a cement-like substance to aid binding of old bone to new bone. In the formation phase, osteoblasts deposit osteoid in the pit, which is then mineralized under osteoblastic control. Quiescence is restored at completion of the cycle. Steroid hormones can influence bone remodelling in a number of ways at any stage throughout the remodelling cycle. They can act directly on osteoblasts and osteoclasts to alter either bone resorption or bone formation. However, it is important to remember that, in vivo, normal bone structure is maintained by complex interactions between osteoblasts and osteoclasts, and it is difficult to consider effects on a single cell type. Steroid hormones may also alter cellular differentiation and\or proliferation and regulate the expression of osteoblast target genes, such as those encoding alkaline phosphatase (AP), osteopontin and osteocalcin. Effects on matrix production or calcification, and cell migration, have also been described.
The actions of steroid hormones on bone in vitro have been studied in a variety of cell systems. A number of osteoblastic cell lines exist ; the most commonly used ones are mouse MC3T3-E1 cells [13] , ROS 17\2.8 and UMR 106 rat osteosarcoma [14, 15] , and the human cell lines TE85 (HOS-TE85), MG-63 and SaOS-2 [16] [17] [18] . Primary cultures are normally prepared from calvarial or trabecular bone. Studies into osteoclast activity have proved to be more difficult. Osteoclasts are difficult to isolate from bone, and until recently no true osteoclastic cell lines existed. Consequently bone marrow cultures, haematopoietic cell lines and cells derived from giant-cell tumours have been used as model systems in which to study osteoclast differentiation and activity. Transgenic mouse technology has now allowed the generation of two osteoclastic cell lines (reviewed in [19] ). So far the number of studies using these systems is very limited compared with those on osteoblastic cells.
The actions of the steroid hormones, retinoids, vitamin D and thyroid hormones are mediated by hormone binding to structurally homologous nuclear receptors, which act as ligand-dependent transcription factors to either activate or repress target gene expression [20, 21] . Members of the steroid\thyroid receptor superfamily regulate gene transcription by binding to similar hormone response element DNA sequences, as either homodimers or heterodimers [22, 23] , with the retinoid X receptor (RXR) functioning as a common heterodimer [24] . The expression of nuclear receptors in bone cells has been studied to varying degrees, with the majority of data focusing on the expression of steroid receptors in osteoblasts. Far fewer studies have examined receptor expression in other bone cells (Table 1 ). The importance of steroid receptor expression in bone is highlighted in receptor knockout animals. This is an emerging area of research that should provide important insight into the physiological requirement for steroid receptor expression for normal skeletal development.
CORTICOSTEROID HORMONES Glucocorticoids
In humans, glucocorticoids enhance bone resorption and decrease bone formation, and consequently lead to a decrease in bone mass [25, 26] . Excess glucocorticoids in vivo, as a result of either prolonged steroid therapy or Cushing's syndrome, are associated with a decrease in bone mineral density (BMD) and in osteopenia, leading to the development of osteoporosis in 30-50 % of cases [27] [28] [29] [30] . The degree of bone loss, which is greater in trabecular than in cortical bone, appears to be related to the duration and dose of treatment [25] .
Robust animal models in which to study osteoporosis are limited [31] , and this is particularly the case for studies of the effects of glucocorticoids on bone. In common with other situations, the rat has been the most popular animal system for studies both in vivo and in vitro. However, results from in vivo studies in rats have been inconsistent, with glucocorticoids inducing both positive and negative effects on rat bone [32] [33] [34] [35] . In addition, the effects of glucocorticoids on bone in vitro are clearly species-dependent. In rats, glucocorticoids increase the differentiation of osteoblasts and osteoblast progenitors [32, 36, 37] , resulting in an induction of the ability of the cells to produce mineralized matrix and bone nodules [37] [38] [39] [40] . Boden et al. [36] demonstrated that some of these differentiation effects are probably mediated via bone morphogenic protein-6. In addition, insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are important in bone development, and may be involved in the glucocorticoid regulation of osteoblast function [41] [42] [43] [44] . This increase in osteoblast differentiation is associated with an induction of osteoblast marker genes. AP mRNA and activity are stimulated by glucocorticoids [39, 45] , as are osteopontin, osteocalcin and bone sialoprotein [39, 40, 46, 47] . Glucocorticoids also have a significant influence on collagen synthesis. They either increase [39, 48] or decrease [48, 49] collagen production, and also cause an osteoblast-specific decrease in the adhesion of bone cells to collagen type I and fibronectin [50] . In addition to stimulating osteoblast activity, glucocorticoids have also been shown to decrease bone resorption in rats, which was paralleled by a decrease in osteoclast numbers, most probably due to osteoclast apoptosis [51] .
In mice, however, the principal effect of glucocorticoids is to stimulate bone resorption and osteoclast formation [52, 53] , an effect which is mediated directly via the glucocorticoid receptor (GR) [52] . Glucocorticoids are also able to modulate osteoclast responsiveness to calcitonin, and this occurs possibly via regulation of calcitonin receptor expression [54] . Additionally, Weinstein et al. [55] demonstrated that glucocorticoid treatment resulted in an inhibition of osteoblastogenesis and the promotion of osteoblast apoptosis, and Bellows et al.
[32] demonstrated a glucocorticoid-mediated inhibition of the proliferation and differentiation of osteoprogenitors. These results were confirmed by a reduction in osteoblast activity, as shown by decreases in AP activity, osteocalcin mRNA and secretion, collagen mRNA levels and synthesis and calcium accumulation [56, 57] . Glucocorticoid-mediated responses operate during a very specific time period, and the effects of dexamethasone on differentiation, in both rats and mice, are most potent when acting on proliferating cells [40, 57] .
Results generated from in vitro studies on human bone cells conflict with in vivo observations and indicate that, contrary to being detrimental, glucocorticoids are actually required for normal osteoblast differentiation and may prevent osteoblast apoptosis under certain conditions [58] . In human osteoblast cultures, dexamethasone increased AP activity [59] [60] [61] [62] [63] and was required for differentiation into a mineralizing, boneproducing osteoblast [61, 63] . The effect of dexamethasone on osteocalcin levels was more variable [59, 60, 62] , and in primary cultures of osteoblasts the responses may be dependent upon the age of the donor [62] . One possible explanation for this conflicting evidence is that glucocorticoids, and steroids in general, exert differential effects on the developing compared with the adult skeleton. Additionally, in vitro studies generally assume that bone cells respond uniformly to hormones, whereas in vivo the response to systemic stimuli is probably highly localized.
GR expression
In humans, alternative splicing of the GR mRNA produces two highly similar isoforms, GRα and GRβ, in which amino acids 1-727 are identical [64] . However, GRβ does not bind ligand and, although it may act as a dominant-negative regulator of GRα activity [65] , it has not been studied in any detail ; thus the data discussed here refer to the GRα isoform. Cytosolic binding studies have shown specific glucocorticoid binding sites in rat and mouse osteoblastic cells [66] [67] [68] [69] [70] [71] . Specific binding has also been demonstrated in human osteoblasts and human osteosarcoma cells [60, [72] [73] [74] . GR mRNA has been detected in human osteoblasts and in the human cells lines SaOS-2, MG-63 and TE85 [60, [74] [75] [76] [77] . The only evidence for GR protein has been provided by Abu et al. [78] , who detected GRs in a number of human bone cells, including osteoblasts, osteocytes and chondrocytes, but they were unable to detect GR expression in osteoclasts.
Mineralocorticoids
There have been very few studies of mineralocorticoid action in bone. Agarwal et al. [79] found that aldosterone significantly inhibited AP activity and enhanced the proliferation of rat calvaria osteoblastic cells, and this was inhibited by two specific mineralocorticoid receptor (MR) antagonists. Some other evidence for the potential role of mineralocorticoids in bone comes from patients with apparent mineralocorticoid excess, an inherited form of hypertension. Apparent mineralocorticoid excess is caused by a deficiency of 11β-hydroxysteroid dehydrogenase, the enzyme responsible for the interconversion of hormonally active cortisol into inactive cortisone [80] . Bone disease was reported in two affected cases, possibly as a result of increased mineralocorticoid activity [81, 82] .
MR expression
In osteoblastic cells derived from newborn-rat calvaria, MR mRNA has been detected by Northern analysis and reverse transcriptase-PCR (RT-PCR). The MR protein was demonstrated by immunoprecipitation and Western blotting, and was localized to the cytosol by immunocytochemistry [79] . RT-PCR and Northern analysis have also demonstrated the presence of mRNA encoding the MR in primary cultures of human osteoblasts and human osteosarcoma cells [74] , although specific MR binding was not detected in any of the osteosarcoma cell lines [74] . Recently we have demonstrated mRNAs for both the GR and the MR in the differentiating human foetal osteoblast cell line SV-HFO (R. Bland and M. Hewison, unpublished work). In a study examining receptor expression in human foetal tissue, both GR and MR mRNAs were localized to osteoblasts at bone-forming sites. The MR was also present in chondrocytes of developing ribs and long bones. However, unlike the GR, which is present throughout gestation, MR mRNA was undetectable after 16 weeks [77] .
It is interesting to note that glucocorticoids act primarily through the GR ; however, in vitro they are also able to bind to the MR with a similar affinity as mineralocorticoids [83] . In classical MR target tissues (kidney, colon), the MR is aldosterone-selective, because glucocorticoids are inactivated by 11β-hydroxysteroid dehydrogenase. Consequently, glucocorticoids can act through the GR or, depending on the activity of the locally expressed 11β-hydroxysteroid dehydrogenase, the MR.
SEX STEROIDS
This group of steroids includes oestrogen, the hormone that is most closely associated with effects on bone. However, androgens and progesterone also play an important role in the maintenance of bone structure.
Oestrogens
Oestrogens are important for the development, maturation and maintenance of the skeleton (reviewed in [84, 85] ). Oestrogen deficiency results in osteoporosis. Postmenopausal bone changes can be prevented or reversed following treatment with oestrogen, and the use of oral contraceptives may exert a beneficial influence on bone mass [84, 86] . Oestrogens have important effects on bone in both males and females. The pubertal growth spurt of both sexes is driven primarily by oestrogens [87] . The importance of oestrogens for the male skeleton is confirmed by the single case report of complete oestrogen resistance in a male [88] . The man, who had a homozygous truncation of the oestrogen receptor (ER) due to a point mutation which produced a premature stop codon in the ER gene, had increased bone turnover, osteoporosis, unfused epiphyses, delayed bone age and continued linear growth into adulthood [88] . This phenotype is very similar to that seen in two aromatasedeficient men (discussed later).
In species other than the human, oestrogens produce effects on bone similar to those seen in humans, and the ovariectomized rat is an useful model for postmenopausal bone loss [84, 89] . Interestingly, Gouveia et al. [90] found that, in rats, physiological doses of thyroxine prevented the bone loss associated with ovariectomy. However, it is not yet known if the cellular and molecular mechanisms of oestrogen action in rodents are the same as in humans.
Oestrogens appear to have effects on both osteoblasts and osteoclasts. 17β-Oestradiol (E # ) has been reported to both stimulate [91, 92] and inhibit [93, 94] osteoblast proliferation. This divergent effect may be dependent upon cell density [94] . E # stimulates the mRNA expression and\or activity of a number of osteoblast marker genes, including collagen type I, osteocalcin, osteopontin, osteonectin and AP [92] [93] [94] [95] [96] . This change in osteoblast markers correlates with an increase in osteoblast differentiation and increased deposition and mineralization of matrix [92] . However, oestrogens primarily regulate bone remodelling by modulating the production of cytokines and growth factors from bone marrow and bone cells (reviewed in [10, 84, 97] ). In osteoblasts derived from various sources, E # has been shown to increase IGF-I levels [91] , decrease interleukin-6 (IL-6) mRNA expression and inhibit the induction of IL-6 by tumour necrosis factor-α [98] . The decrease in BMD generated by ovariectomy in rats is associated with a decrease in transforming growth factor (TGF)-β3 mRNA expression, which is restored by E # therapy [99] . Similar responses have also been seen in a series of experiments using a range of human foetal osteoblastic cell lines transfected with ERs. E # has been shown to increase IGF-I mRNA and bone morphogenic protein-6 mRNA and protein, but did not alter the expression of IGF-II, bone morphogenic protein-1-5 and 7 or TGF-β1 and -β2 [100, 101] . Conversely, E # inhibited IL-6 production [102] . Oestrogen also exerts a significant influence on osteoclast function. A loss of oestrogen stimulates osteoclastogenesis, and this is thought to be mediated primarily by an induction of IL-6 [103] , although there is evidence to suggest that the oestrogenic induction of osteoclast differentiation is mediated via osteoblasts and depends on the presence of IL-6 receptors on osteoblastic cells [97, 104] . It is currently thought that the protective effect of oestrogens in bone may be mediated via regulation of bone cell apoptosis. E # induces apoptosis of isolated osteoclasts [105] , and it has been suggested that this is mediated via TGF-β1 [106] . Similarly, oestrogen loss in ovariectomized rats and in humans undergoing oestrogen withdrawal therapy leads to an increase in the number of apoptotic osteocytes [107, 108] . Conversely, in foetal human osteoblasts E # increased the expression of TIEG (TGF-β-inducible early gene), which has a role in regulating apoptosis [109] .
ER expression
Originally it had been thought that there was only a single ER. However, it is now apparent that, in addition to the original ER (ERα), there is a second receptor subtype, ERβ, which is able to bind oestrogenic compounds [110, 111] . ERα and ERβ are not isoforms of each other, but two distinct proteins encoded by separate genes located on different chromosomes. Therefore, unless ERβ is specified, all the previous studies concentrated on ERα. Despite the obvious importance of oestrogens in bone, ERs have proved difficult to detect. Binding assays have revealed the presence of ERs in rat osteosarcoma cells [112] [113] [114] , mouse osteoblastic cells [70, 71, 115] and human osteoblasts and osteoblastic-like cell lines [71, 112, [116] [117] [118] [119] . K d values for oestradiol binding range from 0.1 nM [119] to 1 nM [112] , and the number of binding sites per cell is generally low (65-825) [71, 112] , although greater numbers of receptors per cell have been reported in some cell systems [70, 118] .
Several studies have confirmed the presence of mRNA encoding the ER in rat, mouse and human osteosarcoma cell lines [71,75,112- 
Androgens
The role of androgens in the maintenance of a normal bone structure has been reviewed previously [151] [152] [153] . Serum androgen levels in females are positively correlated with bone density both pre-and post-menopause [154] [155] [156] . Patients with defective androgen receptors (ARs) often develop osteopenia [157] , and BMD is decreased in females with androgen-insensitivity syndrome, despite appropriate treatment with oestrogen and progesterone [158, 159] . In contrast, the male Tfm (testicular feminization) rat, which is androgen-resistant, develops a female bone phenotype, but is not osteoporotic. It has been suggested that the high oestrogen concentrations produced by aromatization (discussed later) of the non-functional androgens may limit bone defects. This is endorsed by the observation that, if Tfm rats are orchidectomized (and therefore lose the testicular source of oestrogens), they do not achieve a normal trabecular bone volume [160] . Hypogonadism in men is associated with increased bone turnover, which may result in osteoporosis [161, 162] . Testosterone supplementation has been found to increase BMD in eugonadal osteoporotic men [163] [164] [165] . It has even been suggested that glucocorticoid-induced bone loss may be mediated via a decrease in the levels of free testosterone in males [166] . In both asthmatic men and female rats (with cortisol-induced bone loss), testosterone was able to reverse the effects of glucocorticoids [167, 168] .
The most commonly used animal system is the orchidectomized male rat [169] . An imbalance between bone formation and resorption results in the loss of cancellous and cortical bone [170] [171] [172] [173] . The bone loss due to orchidectomy can be prevented by treatment with testosterone and oestrogens [169] [170] [171] . Interestingly, it has also been shown that androgens play a significant role in maintaining bone volume in oestrogen-deficient rats [174] .
Most in vitro studies have demonstrated that androgens stimulate proliferation and differentiation of osteoblasts [70, [175] [176] [177] and osteoblast precursors [37] , and increase AP activity [176] . These responses may be due to alterations in TGF-β mRNA expression and activity [176] [177] [178] . Androgens also mediate osteoclast function. Treatment of osteoclasts with either testosterone or dihydrotestosterone produces a decrease in their bone resorption ability and an increase in TGF-β secretion [179] . Additionally, androgen withdrawal (orchidectomy) results in an increase in osteoclast numbers [180] . This increase in osteoclastogenesis is also seen in bone-marrow-derived stromal cells and is probably due to an increase in IL-6 production [180] .
AR expression
Evidence from the oophorectomized rat and studies using AR antagonists, either in vivo in mice or with human osteoblastic cells in vitro, suggest that the effects of androgens on bone are caused by a direct action on the AR [176, 181] , possibly via an increase in AR numbers or mRNA expression [182, 183] . In keeping with this, ARs have been detected in osteoblasts and osteoclast-like cells.
In 1989 Colvard et al. [184] detected nuclear AR binding in human osteoblast cells. Binding has since been demonstrated in human osteoblasts and osteosarcoma cells [72, 177, [185] [186] [187] [188] . AR binding has also been demonstrated in the rat osteosarcoma cell line UMR 106.01 [185] and in the mouse osteoblastic cell line MC3T3-E1 [70, 189] . The number of binding sites per cell appears to vary greatly and is species-specific, with as few as 70 binding sites in UMR 106.01 cells [185] to more than 14 000 in MC3T3-E1 cells [70] . AR mRNA and protein have also been detected in human osteosarcoma cells [183, 187] and MC3T3-E1 cells [130, 189] . Immunohistochemistry of normal, developing human bone localized ARs to chondrocytes and osteoblasts at sites of bone formation, and to a lesser extent to osteocytes and mononuclear cells within the bone marrow [190] . In a further study, Mizuno et al. [191] detected AR protein in osteoclast-like multinucleated cells obtained from cocultures of mouse osteoblast and bone marrow cells, and AR binding has been demonstrated in avian osteoclasts [179] .
It is important to remember that, as well as activating the AR, androgens can be converted into oestrogens by the enzyme aromatase [192] , and therefore can exert their effects via the AR or via the ER. Females with aromatase deficiency exhibit delayed bone age and have no growth spurt, despite elevated androgen levels [193] . Inhibition of aromatase activity in male rats impairs skeletal modelling and bone maintenance in both growing and aged rats and mimics the effects of orchidectomy [194, 195] , and the aromatase knockout mouse develops osteopenia [196] . Two men with mutations in the aromatase P450 gene demonstrated tall stature, continued growth, delayed skeletal maturation and osteopenia, despite high levels of circulating androgens and the ability to respond to oestradiol [197, 198] . These observations are similar to those seen in the man with a mutation in the ER, re-inforcing the importance of oestrogens for the development of the male skeleton. The relative contribution of androgens\oestrogens in male skeletal homoeostasis has been reviewed recently [199] .
Progesterone
Clinical studies using progesterone treatment have suggested a protective effect on bone mass [200, 201] . Additionally, in glucocorticoid-induced osteoporosis, progesterone treatment caused an increase in trabecular bone density [202] , suggesting that progesterone antagonizes the glucocorticoid-mediated effects, thereby preventing glucocorticoid-induced bone loss [203] . This has also been demonstrated in vitro, where progesterone inhibited the glucocorticoid-induced release of %&Ca from mouse calvarial bone [52] . In postmenopausal women, levels of progesterone as well as oestrogen decrease, and postmenopausal osteoporosis may be due in part to the loss of progesterone. In other situations of low circulating oestrogens, for example in ovariectomized rats (supplemented with progesterone) or pseudopregnant rats, it appears that the bone mass is protected by the high levels of progesterone present [204, 205] .
In cultured rat calvaria, progesterone increases cell proliferation and [$H]proline incorporation into collagen proteins [206] . It also increases osteoblast differentiation, as measured by the increase in AP activity, osteocalcin secretion and the number and area of bone nodules [207] . In bone cell cultures derived from adult rat vertebrae, progesterone stimulates the proliferation and differentiation of osteoprogenitors, increasing the number of bone nodules and AP-positive colonies [208] . Interestingly, this differentiation appears to be sex-dependent, with the effects of progesterone being seen only in osteoprogenitor populations derived from adult female rats, and not in cell populations derived from adult male rats [37] . In contrast with the regulatory effects of the other hormones, IL-6 mRNA and protein were not affected by progesterone in human osteoblasts or human bone marrow stromal cells [209] .
Progesterone receptor (PR) expression
The presence of PRs in human bone has been demonstrated in both osteoblasts and osteoclasts. Progesterone binding was first detected in primary cultures of human osteoblast-like cells [116] , and has since been detected in human osteosarcoma cell lines [131, 133, 220] . However, Orwoll et al. [185] and Wei et al. [210] were unable to detect binding in either UMR 106.01 cells or SaOS-2 cells. PR mRNA and protein have also been detected in human osteoblastic cells [185, [210] [211] [212] , and MacNamara and Loughrey [213] have recently shown that transcripts encoding the A and B forms of the PR (two isoforms transcribed from distinct promoters within the same gene [214] ) are present. Immunohistochemical analysis of human bone localized PR protein to both osteoblasts [215] 
OTHER RELATED (NON-STEROID) HORMONES
This group of hormones includes vitamin D, thyroid hormone and the retinoids. Although these hormones are not steroids, they function via nuclear receptors which form part of the steroid\thyroid receptor superfamily.
Vitamin D
Vitamin D is required for normal bone development, and vitamin D deficiency is associated with rickets in children and osteomalacia in adults (reviewed in [216] However, 1,25(OH) # D $ has a profound effect on the differentiation and proliferation of both osteoblasts and osteoclasts [220, 228] . In common with many other steroids, IL-6 appears to be important, possibly mediating the induction of osteoclastogenesis by 1,25(OH) # D $
[229].
VDR expression
Clear evidence for the importance of VDR expression for normal bone development is seen in the condition of hereditary vitamin D-resistant rickets [217] . Numerous studies have demonstrated the presence of VDRs in rat, mouse and human bone cells using 1,25(OH) . VDR protein has also been detected in rat and human osteosarcoma cells [236, 237] and has been localized to the osteoblasts in rat bone by immunocytochemistry [238] [239] [240] . Johnson et al. [240] specifically studied the expression of the VDR in rats throughout skeletal development. Immunostaining was demonstrated in the mesenchyme condensing to form the vertebral column and limbs on day 13 of gestation, and in the chondrocytes and osteoblasts of limb buds on day 17 of gestation.
There is evidence to suggest that the osteoblastic response to 1,25(OH) # D $ varies in relation to the stage of osteoblast development [40, 222] . It also appears that the expression of VDRs may be dependent upon the stage of osteoblast development. In less well differentiated rat 
Thyroid hormones
The response to thyroid hormones varies depending on the skeletal site [242] . However, thyroid hormones clearly play a role in normal bone development. Increased osteoblast and osteoclast activity in hyperthyroidism leads to increased bone turnover, which may result in osteoporosis [243] [244] [245] . Infantile hyperthyroidism is a disorder sometimes accompanied by secondary craniostenosis, and it appears that the increased bone formation, which leads to premature closure of the sagittal suture, is caused by the thyroid hormone excess [246] . Juvenile hypothyroidism results in delayed skeletal maturation and epiphyseal dysgenesis with long bone growth retardation. In adults, hypothyroidism is associated with reduced bone turnover and osteosclerosis [243, 244] , which is often corrected following thyroid hormone therapy [247] . Although thyroid replacement therapy has been associated with bone loss, this occurs primarily in patients who were previously thyrotoxic and have been rendered hypothyroid by treatment [248] . Perhaps the best evidence for a requirement for 3,3h,5-tri-iodothyronine (T $ ) is seen in syndromes of thyroid hormone resistance, where a mutation in the gene encoding the β form of the thyroid hormone receptor (T $ R) often results in abnormal bone development, which may be characterized by short stature, delayed skeletal maturation and abnormal epiphyseal fusion with stippling [249] .
Rats in which hypothyroidism has been induced show an increase in bone volume [250] and changes to the epiphyseal growth plate [251] . Conversely, hyperthyroid rats show a small increase in the number of eroded surfaces [250] and also demonstrate a decrease in BMD, which varies according to the skeletal site [90, 252] .
Although thyroid hormones stimulate bone resorption directly (as measured by the release of previously incorporated %&Ca) in foetal rat bones [253] , it is unlikely that osteoclasts are the primary T $ target cell. Isolated osteoclasts are unable to respond to T $ and require coculture with other bone cells [244, 254, 255] .
Thyroid hormones have also been shown to regulate a number of osteoblast genes. In rat and mouse osteoblasts, T $ induced AP activity as well as osteocalcin and collagen production [256] [257] [258] [259] [260] . Interestingly, AP activity was unaffected in UMR 106 cells [261] . Thyroid hormones also regulate certain growth factors and cytokines. T $ induces IGF-I and IGFBP-2 mRNA expression in rat primary cultures and osteoblastic cell lines [262, 263] , producing a corresponding rise in protein levels [263] . This increase appears to be dose-dependent, with high concentrations abolishing the effect [264] . IGFBP-4 transcription was increased in MC3T3-E1 cells [265] , and it is possible that this contributes to the anti-proliferative effects of T $ . T $ increased IL-6 and IL-8 mRNA and protein levels in human bone marrow stromal cells and MG-63 cells, although no response was seen in SaOS-2 cells or primary human osteoblasts, and no regulation of IL-1β, IL-3, IL-2 or IL-4 was observed [266] . In contrast, T $ reduced the induction of IL-6 synthesis produced by activators of both the protein kinase C and the protein kinase A pathways in MC3T3-E1 cells [267] .
The regulation of these genes by thyroid hormones appears to be site-specific. Following treatment of rats with thyroxine, in situ hybridization detected a rise in osteocalcin and AP mRNAs in femoral, but not vertebral, osteoblasts [252] . In bone marrow cultures of committed osteoblasts obtained from femoral bone, T $ increased osteocalcin and collagen type I mRNA levels, with only a slight increase in IGF-I mRNA. However, in similar cultures obtained from vertebral bones, T $ had no effect on osteocalcin or collagen type I, but IGF-I mRNA was markedly increased [268] . AP activity was also found to vary between sites [268] . It is probable that this anatomically localized response is not limited to thyroid hormones, but is likely to be common to most steroids (localized bone changes in the oestrogen knockout mouse are discussed later). This would provide an important mechanism for the specificity of hormone action in bone.
At high concentrations, T $ normally decreases cell replication in rat and mouse osteoblastic cell lines [257, 258, 261, 269] and primary cultures of rat osteoblasts [259, 260] . Varga et al. [270] found that T $ did not inhibit DNA synthesis, but increased the number of apoptotic cells. Thyroid hormones appear to have a profound effect on bone cell development. Responses to thyroid hormones vary depending on the stage of osteoblast development [232] , and T $ has been shown to prevent the acquisition of an osteoblast phenotype by MC3T3-E1 cells [269] . It also suppresses the differentiation of osteoprogenitor cells to osteoblasts [271] . Both T $ and to a lesser extent thyroxine induce chondrocyte hypertrophy and matrix formation [272, 273] ; the effects of thyroid hormones on chondrocytes have been reviewed recently [274] . 
Retinoids
The vertebrate limb initially consists of a mesenchymal core covered by a layer of ectoderm. During the elongation of the limbs the apparently homogeneous population of the mesenchymal cells gives rise to different cell types (cartilage, bone and muscle), which develop in appropriate spatial relationships to constitute the developed limb [286] . Retinoic acid (RA) may be the natural morphogen involved in vertebrate limb generation (reviewed in [287] ; the role of retinoids in skeletal morphogenesis has been reviewed recently [288] ). Administration of RA to pregnant mice causes limb dysmorphogenesis in their offspring [289] . In rats, chronic vitamin A toxicosis causes various bone defects, including decreased shaft length and width, metaphyseal flaring, cartilaginous degeneration, osteopenia and fractures [290] . Rats on a high-retinol diet suffered increased bone resorption, osteoporosis, cartilage degeneration and increased metaphyseal vascular penetration [290] . Addition of RA (via the diet) to an in vivo rat model of endochondral bone formation reduced mesenchymal cell proliferation and diminished endochondral bone growth and development [291] .
Chondrocytes, osteoblasts and osteoclasts are all targets for RA action, where it regulates proliferation, differentiation and gene expression. Treatment of chondrocyte cultures with RA and 9-cis-RA rapidly decreases the proliferation and energy status of these cells [292, 293] . RA decreased proliferation of and AP activity in MC3T3-E1 cells [294] , and in UMR 106 and UMR 106-06 cells RA decreased proliferation and induced morphological changes consistent with a less metabolically active cell type [295, 296] . In contrast, RA increased the proliferation of cells obtained from giant-cell tumours, but decreased bone resorption [297] . However, in unfractionated rabbit bone cell cultures RA increased the bone-resorbing activity [298] . Additionally, in similar mouse bone cell cultures, RA stimulated the formation of osteoclast-like cells, and also stimulated osteopontin mRNA expression in isolated osteoclasts [299] .
RA treatment of immature chondrocytes rapidly induced the expression of genes (osteopontin, osteonectin and AP) characteristic of fully mature hypertrophic chondrocytes [300] . In rat and mouse osteoblastic cells, AP mRNA and activity was induced by RA [301] [302] [303] . However, in organ cultures of mouse calvaria and cultures of rat calvaria, AP activity and mRNA levels decreased following treatment with RA, and varied according to the stage of development [304, 305] . RA increased the expression of matrix γ-carboxyglutamic acid-containing protein in human osteoblasts, chondrocytes and fibroblasts [306] . RA stimulated the secretion of osteocalcin in MG-63 cells [307] , but had no effect on osteocalcin secretion in ROS 17\2 cells [308] . However, RA in combination with 9-cis-RA decreased osteocalcin and collagen type I(α1) mRNA levels in ROS 17\2.8 cells [222] . In comparison, RA either alone or in combination with 9-cis-RA increased osteopontin mRNA expression in ROS 25\1 cells and rat calvarial cells [222, 305] .
One important effect of RA is on collagen homoeo-stasis, either by a direct effect on collagen synthesis or via the regulation of collagenase. In human skin fibroblasts and osteoblast-rich rat calvarial cultures, the production of procollagen is decreased by RA [309, 310] . Collagen breakdown (measured by the release of [$H]hydroxyproline) in osteoblast-rich calvarial cultures is stimulated by RA [311] . Collagenase activity and mRNA expression are increased by RA in UMR 106-01 cells [312] and osteoblast-rich calvarial cultures [311] . In contrast, in chondrocytes RA treatment is associated with an increase in the expression of type X [313] and type III collagen mRNAs [314] , but with a decrease in type II collagen transcription and mRNA levels [314] . The effects of RA on cellular differentiation may be mediated by changes in the expression of growth factors, in particular modulation of the IGF\IGFBP axis. In rat foetal calvarial cultures RA induced IGFBP-6 mRNA levels [315] , but decreased the levels of IGF-I and IGF-II mRNAs, although it induced IGF-II polypeptide levels [316] . In various human osteoblast cell systems RA consistently induced IGFBP-6 mRNA, but had variable effects on IGFBP-3, -4 and -5 mRNAs [317] .
Retinoid receptor expression
There are two groups of retinoid receptors : the RA receptors (RARs), whose ligand is all-trans-RA, and the RXRs, whose ligand is 9-cis-RA. 9-cis-RA is not a unique ligand for RXRs. While it binds and activates RXRs, it also binds the RARs with higher affinity [318] . There are at least three RAR genes : RARα [319] , RARβ [320] and RARγ [321] . There are also three RXR genes : RXRα, RXRβ and RXRγ [322] . Each RAR gene generates multiple isoforms [323] , and preliminary evidence indicates that multiple isoforms of the RXRβ and RXRγ genes also exist [324, 325] .
The first description of RAR expression in bone cells was in 1990 by Nakayama et al. [302] , who demonstrated the presence of mRNA encoding RARs in MC3T3-E1 cells, although the authors were not able to conclusively state which isoform was expressed. Also in 1990, Ruberte et al. [326] mapped the expression of RARγ during mouse embryogenesis to limb buds, all cartilages and teeth. Since then a number of reports have demonstrated variable expression of mRNAs encoding the various RAR isoforms in rat and mouse osteoblastic cells (see Table 1 ) [71, 232, 303, [327] [328] [329] . Human osteoblastic cells (both primary cultures and SaOS-2 cells) were shown to contain mRNAs for RARα, RARβ and RARγ [330] . Mahonen and Maenpaa [75] demonstrated RAR mRNA expression in MG-63 cells, but did not specify the isoform. The important role of retinoids on chondrocytes is illustrated by the expression of RARα, RARγ, RXRα and RXRβ mRNAs in cultured chondrocytes [293] .
The first demonstration of an mRNA encoding a RXR was by Kindmark et al. [330] , who demonstrated RXRα mRNA expression in primary cultures of human osteoblastic cells and the human cell line SaOS-2. These results were later confirmed by Jaaskelainen et al. [236] . mRNAs encoding RXRα and RXRβ have been demonstrated in rat osteosarcoma cells [232] , rat bone [328] and MC3T3-E1 cells [329] . Western blotting demonstrated the expression of RARα and RXR proteins in rat osteoblasts and osteosarcoma cells [237] . Using isolated osteoclasts, Saneshige et al. [298] have demonstrated expression of mRNAs for RARα and RXRβ.
Peroxisome-proliferator-activated receptors (PPARs)
The PPAR family consists of three receptors : PPARα, PPARβ (also called δ or NUC-1) and PPARγ [331, 332] . The PPARs appear to play an important role in regulating the differentiation of osteoblastic cells into adipocytelike cells [333, 334] . In situ studies in the rat have indicated that PPARα is expressed exclusively in osteoblasts, especially of young animals. PPARβ can be found in osteoblasts and hypertrophic chondrocytes, and scattered within the haemopoietic marrow. PPARγ is also present in osteoblasts and hypertrophic chondrocytes and in bone marrow stromal cells [335] [336] [337] [338] . Human osteoblast-like cells (SaOS-2, MG-63 and primary cultures) express PPARγ [333, 334] , MC3T3-E1 cells express PPARγ1 but not PPARγ2, whereas ROS17\2.8 express PPARδ [333, 339] .
STEROID RECEPTOR KNOCKOUT ANIMALS
The true importance of steroid receptor action in bone will become apparent with the advent of receptor knockout animals, which may suffer from dysfunction of bone development. This is an area of research that is currently being developed. The bone phenotype of GR, MR and AR knockout animals has yet to be examined, and initial reports have indicated that the PR knockout mouse has no apparent bone defects [340] .
Female ERα knockout mice exhibit decreases in femur length and diameter, but only slight, localized decreases in femur BMD and bone mineral content. In contrast, males show a significant change in BMD, but a lesser change in femur length [341, 342] . It has been suggested that the decrease in BMD is possibly a consequence of increased resorption, as ERα knockout mice have been shown to have a 20 % increase in the numbers of osteoclasts [343] . However, as the decrease in mineralized area and BMD is only approx. 10 % [344] and as no gross abnormalities are detected, the implication is that the ERα is not required, or can be compensated for, during bone development [345] . In addition, the bone loss seen in ERα knockout animals varies depending on the region of the femur examined and increases only selectively with oestrogen therapy, again indicating the potential importance of ERβ [346] . Interestingly, the decrease in femur length seen in ERα knockout mice contrasts with the phenotypes of the ERα-negative man and the two aromatase-deficient men, who exhibited tall stature and unfused epiphyses [88, 197, 198] . It had been hoped that the development of an ERβ knockout mouse would clarify the situation. However, initial studies of the bone phenotype of the ERβ knockout mouse have shown that prepubertal animals and adult males are similar to wildtype mice. In contrast, adult females exhibit changes in their cortical, but not trabecular, bone structure, indicating that ERβ is required for pubertal feminization of the skeleton in mice, but not for the protective effects of oestrogen on trabecular bone [347] . Perhaps the demonstration of ERα and ERβ expression in growth plate chondrocytes [127,139] may go some way towards explaining these results. Oestradiol decreases the recruitment, proliferation and synthetic activity of chondrocytes, leading to maturation of the growth plate and inhibition of long bone growth [84] . Therefore the inability to respond to oestradiol in the ERα-negative man results in unfused epiphyses and a tall stature. Kennedy et al. [138] have recently shown that, in rabbits (a species in which, like humans, epiphyseal closure occurs), ERα is present in the epiphyseal growth plates of both mature males and females. However, in the rat (a species in which epiphyseal closure does not occur), the ERα is only present in immature animals. Therefore developmental loss of ERα expression is associated with loss of the ability to undergo epiphyseal closure. As mice are rodents and therefore would not normally undergo epiphyseal closure, the loss of ERα expression in the knockout animals would perhaps not be expected to induce long bone growth, as it appears to do in humans.
VDR knockout mice display a phenotype that is very similar to that seen in patients with the syndrome of hereditary 1,25(OH)D $ -resistant rickets, although, unlike the VDR knockout mice, this disease is not lethal [217, 348, 349] . However, what is particularly interesting is that the foetuses of VDR knockout mice appear normal, and the knockout phenotype only becomes apparent after weaning (at approx. 3 weeks), becoming more pronounced with age [349, 350] . Post-weaning VDR-null mutant mice show marked growth retardation such that, at 6 weeks of age, the homozygote animals have a body weight of only 50 % of that of the wild-type animals. They have low serum calcium and phosphate, and increased AP activity. They exhibit a low bone density (decreased by 40 % compared with the wild type). The tibia and fibula show features typical of advanced rickets, such as inadequate mineralization, a loss of the orderly arrangement of chondrocytes and widening of the layers of chondrocytes in the epiphyseal growth plates [348] [349] [350] . Supplementation with calcium significantly improves the impaired mineralization, but not the disordered proliferation\differentiation of chondrocytes [348] . The time of onset of a knockout phenotype may be related to the mechanism of calcium absorption. In rats calcium is absorbed by a 1,25(OH) # D $ -independent mechanism for the first 18 days of life, which is then gradually replaced by a 1,25(OH) # D $ -dependent component [349] . Although 1,25(OH) # D $ plays a role in the formation of osteoclasts, the number of osteoclasts appeared to be normal in the VDR knockout mice [348] . Recent evidence has suggested that, although 1,25(OH) # D $ -driven osteoclastogenesis is mediated by VDR-expressing osteoblasts, osteoclasts can also be formed under the influence of parathyroid hormone or IL-1α in the absence of VDR-mediated effects [351] .
Deletion of T $ Rβ has demonstrated the importance of the T $ Rβ gene for auditory function, but T $ Rβ1 knockout animals exhibit no major bone phenotype [352] . However, animals in which the T $ Rα gene has been disrupted, thereby preventing production of both T $ Rα1 and cerbAα2, exhibit impaired mineralization, delayed ossification of epiphysis and diaphysis, and early lethality [353] . In particular, the growth cartilage was thinner and contained more chondrocytes, but there was a decrease in the number of hypertrophic chondrocytes, and the chondrocyte column was disrupted and randomly arranged. The calcium content of the skeletons was also lower [353] . These effects could be rescued by thyroxine treatment, presumably acting via the T $ Rβ. A more recent development is mice lacking both T $ Rα1 and T $ Rβ [354] . These mice suffer from decreased weight and shorter femurs and tibias. Both bone mineral content and bone area of the femur, tibia and vertebrae were significantly decreased, although there was no difference in BMD. Additionally, the growth plates were disorganized with no columnar structure and cartilage in the epiphysis, which leads to delayed ossification [354] .
The number of receptor isoforms and the possible combination of receptor knockouts complicates the situation in retinoid receptor knockout animals. Initial studies looked at single-receptor deletions. RARα1, RARβ2 and RARγ2 knockout mice all appear normal [355] [356] [357] [358] and demonstrate no skeletal abnormalities. Mice deficient in all isoforms of RARα displayed webbed digits on the forelimbs and hindlimbs, but the defects were restricted to soft tissues [356] . Interestingly, mice in which RARα1 was overexpressed developed limb defects similar to those seen in animals administered high doses of RA [359] . It was found that overexpression of RARα1 interfered with chondrogenesis in the hindlimb by delaying chondroprogenitor differentiation, and the authors suggested that continued expression of RARα in cells destined to become chondroblasts contributes to a different cellular fate [359] . In contrast, animals deficient in all isoforms of RARγ were growth-deficient and exhibited a number of skeletal malformations [355] . Defects included ossified fusion between the basioccipital and anterior arch of the atlas, fusion of the first and second ribs, fused vertebrae and homoeotic trans-formations along the antero-posterior axis, indicating that RA is required for proper specification of some cervical and thoracic vertebrae. However, as in the RARα knockout mice, no limb malformations were detected. Additionally, the defects in the RARγ mice demonstrated incomplete penetrance and expressivity, suggesting that some functional redundancy exists between the receptors. This was confirmed by the generation of double knockouts. RARα\γ mutants consistently exhibited skeletal malformations [360] . Lohnes et al. [360] generated various RAR double mutants, all of which exhibited bone defects. Abnormalities of the axial skeleton occurred in all mutants, and included a number of homoeotic transformations and various malformations such as rib fusion, basioccipital-exoccipital fusion, defects in cervical neural arches and ectopic bone production. Craniofacial abnormalities were detected in all mutants except RARα\ β2, RARα1\β2 and RARβ2\γ. Interestingly, the limbs of all double mutants were essentially normal, with the exception of RARα\γ knockout mice, which demonstrated a number of malformations [360] . The various defects exhibited by RAR knockout animals have been reviewed by Lohnes et al. [361] .
RXRα knockout mice have normal limb development (although other tissues are affected) and are resistant to RA-induced limb deformities, thereby implicating RXRα as a component in the teratogenic process in limbs [362] . Triple RXRα\β\γ knockout mice were shown to be growth-deficient, but exhibited no gross abnormalities [363] .
FUTURE CONSIDERATIONS
Previously, work has concentrated on the investigation of osteoblast function. However, there is now an increasing awareness of the important role that other bone cells, such as chondrocytes and osteoblast and osteoclast precursor cells, play in steroid-mediated responses. It is also important to remember that, in vivo, the response to steroids will occur as a result of a combination of factors, acting on a mixture of bone cells. For example, despite the facts that androgens clearly regulate both osteoblast and osteoclast function and that ARs are present in both cell types, it appears that cells of the osteoblast lineage are required to mediate the effects of androgen withdrawal. Orchidectomy of SAMP6 mice (a model of defective osteoblast development) failed to produce the expected bone loss [364] . Furthermore, in addition to modulating target gene transcription, steroids also regulate the numbers, binding capacity and expression of their own and other receptors within the receptor superfamily. -mediated responses [365] . Glucocorticoids also increase VDR numbers and stimulate cell responsiveness to 1,25(OH) # D $ in rat osteoblasts [366] , but decrease VDR expression in human osteosarcoma cells [367] .
It is also important to determine the cellular expression of all members of the steroid\thyroid receptor family. Although it is the RXR heterodimers that are thought to be the predominantly functionally active complexes [368, 369] , the steroid receptors are also capable of promiscuous interactions with other members of the steroid receptor superfamily [370] [371] [372] . Therefore the co-expression of more than one steroid receptor per cell could provide an array of possible heterodimeric complexes, which would form the basis for complex interaction among their signalling pathways, and competition between steroid receptors for heterodimer partners will regulate steroid hormone responsiveness.
Another component that may prove to be important for the development of bone disease is the genetic variability in steroid receptors. It had been suggested that polymorphisms in the VDR could be used to predict bone turnover [373] . However, the relationship between VDR polymorphisms and bone density remains controversial ; much of the data has been reviewed by Cooper and Umbach [374] , who concluded that VDR polymorphisms represent just one genetic determinant of BMD. Kobayashi et al. [375] suggested a similar relationship between polymorphisms of the ER gene and BMD, although in similar studies by Mizunuma et al. [376] and Gennari et al. [377] only a slight, nonsignificant relationship was observed. It appears likely that individual polymorphisms are not so important, but can lead jointly to increased susceptibility [378] .
The field of steroid hormone action has become increasingly more complex. Although the steroid receptors have a very important role to fulfil, they are just one of a number of factors that must be considered. Until recently our established understanding of receptor action was that liganded steroid receptors bind to specific DNA sequences, as either homodimers or heterodimers, to regulate gene transcription [22] . However, it is now apparent that this initial concept is very simplistic and that a range of accessory proteins (including co-repressors and co-activators) also participate in the process (reviewed in [379] ). A number of these proteins have now been identified, some of which maybe receptor-specific [380] . It is also possible that structural differences between receptor isoforms, such as those seen in ERα and ERβ [111] , will influence the ability of receptors to interact with co-repressors and co-activators, and therefore modulate steroid responsiveness. In addition to the genomic actions of steroid hormones, there is increasing evidence suggesting that steroids are also able to elicit rapid, non-genomic actions (reviewed in [381] ). These effects have been demonstrated for virtually all steroids and probably occur via specific membrane receptors [382] . Membrane binding sites for oestrogen have been identified in a human pre-osteoclastic cell line [383] , and recent studies have identified membrane receptors for 1,25(OH) # D $ and 24,25(OH) # D $ in rat chondrocytes and chick tibia [384] [385] [386] . The physiological importance of these non-genomic actions has yet to be determined.
As our understanding of the mechanisms of steroid action in bone grows, hopefully we will be able to design novel therapeutic agents. Non-steroidal selective modulators of the ER (SERMs) are now beginning to be used therapeutically to prevent postmenopausal bone loss [387] . However, there may better receptor targets, and the discovery of further receptor isoforms (the expression of which may be site-and developmentspecific) and novel ligands may provide a range of effective modulators of bone homoeostasis. 
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